Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives $6.23 Average PT from Analysts

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has been given a consensus recommendation of “Hold” by the seven analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $6.2333.

A number of brokerages recently commented on IRWD. Weiss Ratings restated a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, April 27th. Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Sunday. Jefferies Financial Group restated a “hold” rating and set a $3.70 price objective on shares of Ironwood Pharmaceuticals in a report on Thursday, February 26th. Finally, Citizens Jmp raised their price objective on shares of Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th.

Insider Activity at Ironwood Pharmaceuticals

In related news, Director Alexander J. Denner sold 6,730,800 shares of the firm’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $3.05, for a total transaction of $20,528,940.00. Following the sale, the director directly owned 9,188,635 shares in the company, valued at $28,025,336.75. This trade represents a 42.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 9.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IRWD. Integrated Wealth Concepts LLC increased its stake in Ironwood Pharmaceuticals by 21.4% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 3,406 shares during the last quarter. LSV Asset Management acquired a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at $30,000. Captrust Financial Advisors acquired a new stake in Ironwood Pharmaceuticals in the 2nd quarter valued at $32,000. Jump Financial LLC acquired a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at $34,000. Finally, DGS Capital Management LLC acquired a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at $35,000.

Ironwood Pharmaceuticals Stock Down 2.2%

Shares of NASDAQ IRWD opened at $3.50 on Friday. The company’s fifty day moving average is $3.74 and its 200-day moving average is $3.74. The stock has a market cap of $570.71 million, a price-to-earnings ratio of 5.83 and a beta of 0.29. Ironwood Pharmaceuticals has a twelve month low of $0.55 and a twelve month high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%.The company had revenue of $106.51 million for the quarter, compared to analyst estimates of $92.11 million. On average, research analysts anticipate that Ironwood Pharmaceuticals will post 0.88 EPS for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.